Drug Profile
Ripertamab - Sinocelltech
Alternative Names: Recombinant chimeric anti-CD20 monoclonal antibody - Sinocelltech; SCT-400Latest Information Update: 06 Mar 2022
Price :
$50
*
At a glance
- Originator Sinocelltech
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apoprotein stimulants; Apoptosis stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
Most Recent Events
- 11 Dec 2021 Safety and efficacy data from a phase III trial in Diffuse large B cell lymphoma presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2021)
- 11 Dec 2021 Sinocelltech completes a phase-III trial in Diffuse large B cell lymphoma (First-line therapy, Combination therapy) in China (IV) (NCT02772822)
- 06 Apr 2021 Ripertamab is still in phase III trial for Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in China (IV)